Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹2,420.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹315.55B
Enterprise Value₹348.52B
Total Cash (Recent Filing)₹9.30B
Total Debt (Recent Filing)₹24.56B
Price to Earnings (P/E)148.1
Beta1.39
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery & Return To ProfitA restored top-line trajectory with ~12% revenue growth and a return to net profitability (~₹2.13B) signals the business has re‑stabilized operationally. Sustained revenue recovery supports reinvestment, deleveraging and long‑term funding for R&D or commercialization programs if management sustains execution.
Manageable Leverage & Stronger Equity BaseStable debt levels and a materially larger equity base (~₹49.4B) improve balance‑sheet cushioning versus prior years. This reduces near‑term refinancing risk and provides capacity for capex, regulatory investments or tuck‑in M&A, increasing strategic optionality if operational improvements persist.
Diversified Revenue StreamsA multi‑pronged business model—branded/finished formulations, API supply and contract manufacturing—lowers reliance on any single product or market. Diversification across product types and client channels can stabilize cash flows and allow scale leverage in manufacturing and regulated‑market supply with successful approvals.
Bears Say
Multi-year Inconsistent ProfitabilityHistoric multi‑year losses and swings in operating results indicate earnings are not yet structurally reliable. Repeated profitability lapses can impair stakeholder confidence, constrain long‑term planning and require persistent margin or mix improvements to ensure this year’s profits are durable rather than cyclically driven.
Weak And Volatile Free Cash FlowModest and declining free cash flow limits the firm’s ability to reduce debt, increase strategic investments, or return capital. Volatility in cash conversion heightens refinancing and working‑capital risk, and means reported profits may not translate reliably into cash for growth initiatives or balance‑sheet strengthening.
Volatile Operating Margins & Earnings QualityFrequent swings in EBIT and uneven margin performance reduce predictability of returns on invested capital and complicate pricing, portfolio and capital allocation decisions. Persistent earnings volatility can raise borrowing costs and slow investment in higher‑margin specialty projects that require multi‑period funding.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹2420.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹315.55B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Aug 07, 2026 which is in 36 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on May 04, 2026. The company reported ₹10.23 earnings per share for the quarter, beating the consensus estimate of N/A by ₹10.23.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹10.23 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.216%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Alkem Laboratories Ltd.
―
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―